These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

137 related items for PubMed ID: 23264156

  • 1. Successful treatment of multicentric Castleman's disease accompanying myeloma with bortezomib.
    Khan AA, Siraj F, Bhargava M, Aggarwal S.
    BMJ Case Rep; 2012 Dec 20; 2012():. PubMed ID: 23264156
    [Abstract] [Full Text] [Related]

  • 2. Treatment of multicentric Castleman's Disease accompanying multiple myeloma with bortezomib: a case report.
    Yuan ZG, Dun XY, Li YH, Hou J.
    J Hematol Oncol; 2009 Apr 28; 2():19. PubMed ID: 19400935
    [Abstract] [Full Text] [Related]

  • 3. Multicentric Castleman's disease in HIV infection: a systematic review of the literature.
    Mylona EE, Baraboutis IG, Lekakis LJ, Georgiou O, Papastamopoulos V, Skoutelis A.
    AIDS Rev; 2008 Apr 28; 10(1):25-35. PubMed ID: 18385778
    [Abstract] [Full Text] [Related]

  • 4. Successful treatment with bortezomib and thalidomide for POEMS syndrome associated with multicentric mixed-type Castleman's disease.
    Wang X, Ye S, Xiong C, Gao J, Xiao C, Xing X.
    Jpn J Clin Oncol; 2011 Oct 28; 41(10):1221-4. PubMed ID: 21890654
    [Abstract] [Full Text] [Related]

  • 5. Successful bone reconstruction after bortezomib therapy in a myeloma patient.
    Tanaka T, Yamasaki R, Omura H, Hino N.
    Int J Hematol; 2011 Sep 28; 94(3):221. PubMed ID: 21861100
    [No Abstract] [Full Text] [Related]

  • 6. Complete remission of multiple myeloma associated scleredema after bortezomib-based treatment.
    Szturz P, Adam Z, Vašků V, Feit J, Krejčí M, Pour L, Hájek R, Mayer J.
    Leuk Lymphoma; 2013 Jun 28; 54(6):1324-6. PubMed ID: 23061634
    [No Abstract] [Full Text] [Related]

  • 7. HHV-8-associated multicentric Castleman's disease in HIV-negative patient: a novel therapy for an orphan disease.
    Sbenghe MM, Besa E, Mahipal A, Dulau Florea A, Bray P, Caro J.
    Oncologist; 2012 Jun 28; 17(1):145-6; author reply 147-8. PubMed ID: 22286773
    [Abstract] [Full Text] [Related]

  • 8. Induction treatment of light chain deposition disease with bortezomib: rapid hematological response with persistence of renal involvement.
    Minarik J, Scudla V, Tichy T, Pika T, Bacovsky J, Lochman P, Zadrazil J.
    Leuk Lymphoma; 2012 Feb 28; 53(2):330-1. PubMed ID: 21883030
    [No Abstract] [Full Text] [Related]

  • 9. [Two HHV8-related illnesses in a HIV-negative patient: Kaposi's sarcoma and multicentric Castleman's disease. Response to treatment with Rituximab and CHOP].
    Pastor MA, Vasco B, Mosquera JM, Debén G, Bautista P, Requena L.
    Actas Dermosifiliogr; 2006 Feb 28; 97(6):385-90. PubMed ID: 16956518
    [Abstract] [Full Text] [Related]

  • 10. Bortezomib-induced acute pancreatitis in a patient with multiple myeloma.
    Wang HH, Tsui J, Wang XY, Liu SS, Li J.
    Leuk Lymphoma; 2014 Jun 28; 55(6):1404-5. PubMed ID: 23927397
    [No Abstract] [Full Text] [Related]

  • 11. POEMS syndrome, osteosclerotic myeloma and Castleman's disease: a case report.
    Bosco J, Pathmanathan R.
    Aust N Z J Med; 1991 Aug 28; 21(4):454-6. PubMed ID: 1953537
    [Abstract] [Full Text] [Related]

  • 12. Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma.
    Federico V, Breccia M, Petrucci MT, Loglisci G, Mansueto G, Mercanti C, Levi A, Cartoni C, Musto P, Alimena G.
    Clin Adv Hematol Oncol; 2012 Apr 28; 10(4):266-8. PubMed ID: 22706491
    [No Abstract] [Full Text] [Related]

  • 13. Interstitial pneumonitis caused by Pneumocystis jirovecii pneumonia (PCP) during bortezomib treatment.
    Wondergem MJ, Grünberg K, Wittgen BP, Sonneveld P, Zweegman S.
    Histopathology; 2009 Apr 28; 54(5):631-3. PubMed ID: 19302537
    [No Abstract] [Full Text] [Related]

  • 14. Diagnosis and the current trends in multiple myeloma therapy.
    Dmoszyńska A.
    Pol Arch Med Wewn; 2008 Oct 28; 118(10):563-6. PubMed ID: 19112817
    [Abstract] [Full Text] [Related]

  • 15. Bortezomib just for induction or also for maintenance in myeloma patients with renal impairment?
    San Miguel JF.
    Haematologica; 2014 Jan 28; 99(1):5-6. PubMed ID: 24425688
    [No Abstract] [Full Text] [Related]

  • 16. Hematology: first-line bortezomib benefits patients with multiple myeloma.
    Dimopoulos MA, Terpos E.
    Nat Rev Clin Oncol; 2009 Dec 28; 6(12):683-5. PubMed ID: 19942924
    [Abstract] [Full Text] [Related]

  • 17. Bortezomib-based therapy as induction regimen of an autograft program in front-line treatment of multiple myeloma with end-stage renal disease.
    Siniscalchi A, Dentamaro T, Perrotti A, Tatangelo P, de Fabritiis P, Caravita T.
    Ann Hematol; 2010 Aug 28; 89(8):821-2. PubMed ID: 19953253
    [No Abstract] [Full Text] [Related]

  • 18. Effects of bortezomib on bone disease in multiple myeloma.
    Drake MT, Rajkumar SV.
    Am J Hematol; 2009 Jan 28; 84(1):1-2. PubMed ID: 19030185
    [No Abstract] [Full Text] [Related]

  • 19. A striking response to bortezomib in a patient with pleural localization of multiple myeloma.
    Mangiacavalli S, Varettoni M, Zappasodi P, Pica G, Lazzarino M, Corso A.
    Leuk Res; 2009 Apr 28; 33(4):577-8. PubMed ID: 18842298
    [No Abstract] [Full Text] [Related]

  • 20. [Salvage therapy with proteasome inhibitor bortezomib for relapsed and refractory multiple myeloma].
    Huang WR, Li R, Jing Y, Zhang YZ, Wu XX, Gao CJ, Bo J, Yu L, Wang QS, Da WM.
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2006 Dec 28; 14(6):1146-50. PubMed ID: 17204182
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.